Overview

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After P

Status:
RECRUITING

Trial end date:
2029-06-30

Target enrollment:

Participant gender:

Summary

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.

Phase:

PHASE3

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Androgen Antagonists
apalutamide